Demonstration of dual pharmacology in vivo of PF-3429281: A novel inhaled dual antimuscarinic/β2 agonist

J. Philip, A. Gray, N. Clarke, M. Yeadon, C. Perros-Huguet (Sandwich, United Kingdom)

Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Session: Regulation of airway hyperresponsiveness and bronchodilators
Session type: Thematic Poster Session
Number: 1231
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Philip, A. Gray, N. Clarke, M. Yeadon, C. Perros-Huguet (Sandwich, United Kingdom). Demonstration of dual pharmacology in vivo of PF-3429281: A novel inhaled dual antimuscarinic/β2 agonist. Eur Respir J 2010; 36: Suppl. 54, 1231

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The in-vitro pharmacology of PF-3429281 – A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010

The in-vitro pharmacology of PF-4522971 – A novel inhaled Muscarinic M3 Antagonist
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010

The in vitro biology of PF-00610355 – a novel β2 adrenoceptor agonist with a long duration of action
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009

Safety and toleration of pf-00610355, a novel inhaled long acting β2 adrenoreceptor agonist
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

In vitro pharmacological characterization of the novel inhaled bronchodilator CHF6366 acting as dual muscarinic antagonist/ß2-agonist (MABA)
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

PF-3429281 – A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist in the anaesthetised dog model of bronchoconstriction
Source: Annual Congress 2010 - Bronchodilators in airways disease
Year: 2010

Efficacy of UR-63325, a new H4 receptor antagonist, in two rodent asthma models
Source: Annual Congress 2010 - Models of airways disease
Year: 2010


Assessing the therapeutic benefit of a new inhaled QD LABA through population PK-safety & efficacy modelling
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

A dual-acting muscarinic antagonist, ß2-agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Year: 2012

PF-00610355 – an inhaled β2 adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009

A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy
Source: Annual Congress 2011 - Models of disease and drug actions
Year: 2011

In vitro pharmacological characterization of two novel dual-acting MABA compounds (LAS190792 and LAS191351)
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014

Pharmacological profile of a novel, potent and oral TRPA1 antagonist. Characterization in a preclinical model of induced cough
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

Optimization of inhalation treatment – Evaluation of influence of PNEUMOlogic® and Optimiser® spacers on aerosol particle distribution from pMDI-EB
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011


Bronchoprotective activity and safety assessment of two novel dual-acting MABA compounds (LAS190792 and LAS191351) in dogs
Source: International Congress 2014 – Novel targets and drugs for asthma and COPD
Year: 2014

Combined inhaled corticosteroid and long acting β agonist treatment of paediatric asthma: experience of an asthma care programme
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009


Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
Source: Eur Respir Rev 2015; 25: 54-64
Year: 2016



Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2-adrenoreceptor agonist
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


β2 long-acting and anticholinergic drugs synergistically control TGFβ1-mediated neutrophilic inflammation in COPD: An "in vitro" model
Source: Annual Congress 2011 - COPD: clinical studies and animal cell models
Year: 2011